Patents by Inventor Thomas M. Jessell

Thomas M. Jessell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9765297
    Abstract: The present invention relates to culture systems comprising differentiated stem cells, that may be used for identifying agents useful in treating degenerative nervous system disorders and are suitable for high-throughput screening applications. It is based, at least in part, on the discovery that co-cultures of (i) astrocytes expressing a mutated SODI gene and (ii) stem-cell derived motor neurons manifested cell death via a Bax-dependent mechanism, and modeled motor neuron death in amyotrophic lateral sclerosis.
    Type: Grant
    Filed: April 10, 2008
    Date of Patent: September 19, 2017
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Serge Przedborski, Hynek Wichterle, Makiko Nagai, Thomas M. Jessell
  • Patent number: 8969081
    Abstract: Disclosed are methods for generating a neuron expressing Hoxc8 transcription factor or a caudal motor neuron comprising culturing an embryonic stem cell in a composition which is essentially free of retinoids and comprises an isotonic salt solution, so as to generate the neuron which expresses Hoxc8 transcription factor or the caudal motor neuron. Disclosed are also methods for generating a caudal brachial motor neuron, a thoracic motor neuron, or a lumbar motor neuron from an embryonic stem cell in a composition essentially free of retinoids and comprising ADFNK medium, an amount of FGF-2, or Gdf11 respectively. Disclosed are also methods of transplanting a motor neuron into a subject comprising generating the motor neuron and transplanting the motor neuron into the subject. Disclosed is also a population of motor neuron cells enriched for motor neuron cells expressing Foxp1 and expressing a gene associated with Spinal Muscular Atrophy (SMA) or Amyotrophic Lateral Sclerosis (ALS).
    Type: Grant
    Filed: December 9, 2009
    Date of Patent: March 3, 2015
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Hynek Wichterle, Thomas M. Jessell, Mirza Peljto
  • Publication number: 20100267073
    Abstract: The present invention relates to culture systems comprising differentiated stem cells, that may be used for identifying agents useful in treating degenerative nervous system disorders and are suitable for high-throughput screening applications. It is based, at least in part, on the discovery that co-cultures of (i) astrocytes expressing a mutated SODI gene and (ii) stem-cell derived motor neurons manifested cell death via a Bax-dependent mechanism, and modeled motor neuron death in amyotrophic lateral sclerosis.
    Type: Application
    Filed: April 10, 2008
    Publication date: October 21, 2010
    Inventors: Serge Przedborski, Hynek Wichterle, Makiko Nagai, Thomas M. Jessell
  • Publication number: 20100196332
    Abstract: Disclosed are methods for generating a neuron expressing Hoxc8 transcription factor or a caudal motor neuron comprising culturing an embryonic stem cell in a composition which is essentially free of retinoids and comprises an isotonic salt solution, so as to generate the neuron which expresses Hoxc8 transcription factor or the caudal motor neuron. Disclosed are also methods for generating a caudal brachial motor neuron, a thoracic motor neuron, or a lumbar motor neuron from an embryonic stem cell in a composition essentially free of retinoids and comprising ADFNK medium, an amount of FGF-2, or Gdf11 respectively. Disclosed are also methods of transplanting a motor neuron into a subject comprising generating the motor neuron and transplanting the motor neuron into the subject. Disclosed is also a population of motor neuron cells enriched for motor neuron cells expressing Foxp1 and expressing a gene associated with Spinal Muscular Atrophy (SMA) or Amyotrophic Lateral Sclerosis (ALS).
    Type: Application
    Filed: December 9, 2009
    Publication date: August 5, 2010
    Inventors: Hynek Wichterle, Thomas M. Jessell, Mirza Peljto
  • Patent number: 7393686
    Abstract: This invention provides a method of converting a stem cell into a ventral neuron which comprises introducing into the stem cell a nucleic acid which expresses homeodomain transcription factor Nkx6.1 protein in the stem cell so as to thereby convert the stem cell into the ventral neuron. Provided are methods of diagnosing a motor neuron degenerative disease in a subject. Also provides is a method of treating neuronal degeneration in a subject which comprises implanting in diseased neural tissue of the subject a neural stem cell which comprises an isolated nucleic acid molecule which is capable of expressing homeodomain Nkx6.1 protein under conditions such that the stem cell is converted into a motor neuron after implantation, thereby treating neuronal degeneration in the subject.
    Type: Grant
    Filed: September 1, 2000
    Date of Patent: July 1, 2008
    Assignees: Trustees of Columbia University in the City of New York, The Regents of the University of California
    Inventors: Thomas M. Jessell, James Briscoe, Johan Ericson, John L. R. Rubenstein, Maike Sander
  • Patent number: 7312081
    Abstract: This invention provides a method of converting a stem cell into a ventral neuron which comprises introducing into the stem cell a nucleic acid which expresses homeodomain transcription factor Nkx6.1 or Nkx6.2 protein in the stem cell so as to thereby convert the stem cell into the ventral neuron. Provided are methods of diagnosing a motor neuron degenerative disease in a subject. Also provides is a method of treating neuronal degeneration in a subject which comprises implanting in diseased neural tissue of the subject a neural stem cell which is capable of expressing homeodomain Nkx6.1 or Nkx6.2 protein under conditions such that the stem cell is converted into a motor neuron after implantation, thereby treating neuronal degeneration in the subject.
    Type: Grant
    Filed: August 31, 2001
    Date of Patent: December 25, 2007
    Assignees: The Trustees of Columbia University in the City of New York, The Regents of the University of California
    Inventors: Thomas M. Jessell, James Briscoe, Johan Ericson, John L. R. Rubenstein, Maike Sander
  • Patent number: 7192916
    Abstract: This invention provides isolated nucleic acids encoding a motor neuron restricted MNR2 protein, and a homeobox HB9 protein. Also provided are purified MNR2 and HB9 proteins, antibodies recognizing these proteins, transgenic animals expressing these proteins, and functionally equivalent analogs of these proteins. Finally, methods are disclosed for inducing differentiation of somatic motor neurons, and for treating diseases related to the lack of normally functioning motor neurons, neurodegenerative diseases, acute nervous system injury, and neuromuscular disease.
    Type: Grant
    Filed: March 29, 2001
    Date of Patent: March 20, 2007
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Thomas M. Jessell, Yasuto Tanabe, Christopher William
  • Patent number: 7074771
    Abstract: This invention provides an isolated nucleic acid molecule encoding a motor neuron restricted pattern, MNR2, protein. This invention provides an isolated nucleic acid molecule of at least 15 contiguous nucleotides capable of specifically hybridizing with a unique sequence included within the sequence of the nucleic acid molecule encoding a MNR2 protein. This invention provides a purified MNR2 protein, a polyclonal and monoclonal antibody directed to an epitope of an MNR2 protein. This invention provides a method of inducing differentiation somatic motor neurons which comprises expressing MNR2 protein in any neural progenitor cells. This invention provides a transgenic animal which expresses an MNR2 protein. This invention provides a pharmaceutical composition comprising a MNR2 protein and pharmaceutically acceptable carrier.
    Type: Grant
    Filed: March 11, 2002
    Date of Patent: July 11, 2006
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Thomas M. Jessell, Yasuto Tanabe, Christopher William
  • Patent number: 6955802
    Abstract: Provided are genetically engineered cells comprising a neural stem cell and retroviral expression system in the neural stem cell, which is capable of expressing homeodomain transcription factor Nkx6.1 protein but does not express homeodomain transcription factor Irx3 protein or homeodomain transcription factor Nkx2.2 protein; which is capable of expressing homeodomain transcription factor Nkx6.1 protein and homeodomain transcription factor Irx3 protein; and which is capable of expressing homeodomain transcription factor Nkx2.2 protein or homeodomain transcription factor Nkx2.9 protein. Also provided are methods of generating such genetically engineered motor neurons, V2 neurons, and V3 neurons.
    Type: Grant
    Filed: May 11, 2000
    Date of Patent: October 18, 2005
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Thomas M. Jessell, James Briscoe, Johan Ericson
  • Patent number: 6916913
    Abstract: This invention provides an isolated vertebrate nucleic acid molecule which encodes dorsalin-1. This invention also provides a nucleic acid probe capable of specifically hybridizing with a sequence included within the sequence of a nucleic acid molecule encoding a dorsalin-1. The invention also provides a vector and host vector system for the production of a polypeptide having the biological activity of dorsalin-1 which comprises the above-described vector in a suitable host. This invention also provides a purified vertebrate dorsalin-1. This invention provides a method for stimulating neural crest cell differentiation, a method for regenerating nerve cells, a method for promoting bone growth, a method for promoting wound healing and a method for treating neural tumor using purified dorsalin-1. This invention further provides a pharmaceutical composition comprising purified dorsalin-1 and a pharmaceutically acceptable carrier. Finally, this invention provides an antibody capable of binding to dorsalin-1.
    Type: Grant
    Filed: November 2, 2001
    Date of Patent: July 12, 2005
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Thomas M. Jessell, Konrad Basler, Toshia Yamada
  • Publication number: 20040053210
    Abstract: This invention provides a method of converting a stem cell into a ventral neuron which comprises introducing into the stem cell a nucleic acid which expresses homeodomain transcription factor Nkx6.1 or Nkx6.2 protein in the stem cell so as to thereby convert the stem cell into the ventral neuron. Provided are methods of diagnosing a motor neuron degenerative disease in a subject. Also provides is a method of treating neuronal degeneration in a subjet which comprises implanting in diseased neural tissue of the subject a neural stem cell which is capable of expressing homeodomain Nkx6.1 or Nkx6.2 protein under conditions such that the stem cell is converted into a motor neuron after implantation, thereby treating neuronal degeneration in the subject.
    Type: Application
    Filed: August 1, 2003
    Publication date: March 18, 2004
    Inventors: Thomas M. Jessell, James Briscoe, Johan Ericson, John L.R. Rubenstein, Maike Sander
  • Publication number: 20040014210
    Abstract: The present invention provides a method for inducing differentiation of an embryonic stem cell into a differentiated neural cell. The present invention further provides a method for producing differentiated neural cells, and a population of cells comprising the differentiated neural cells. Additionally, the present invention provides a method for repopulating a spinal cord in a subject, and a method for treating nervous tissue degeneration in a subject in need of treatment. The present invention further provides neural progenitor cells, differentiated neural cells, and uses of same. Also provided is a transgenic non-human animal containing the differentiated neural cells. The present invention is further directed to a method for isolating a population of differentiated neural cells. Finally, the present invention provides a method for identifying an agent for use in treating a condition associated with neuron degeneration.
    Type: Application
    Filed: July 16, 2002
    Publication date: January 22, 2004
    Inventors: Thomas M. Jessell, Hynek Wichterle, Ivo Lieberam
  • Publication number: 20040005602
    Abstract: This invention provides an isolated nucleic acid molecule encoding a vhh-1 protein, an isolated protein which is a vhh-1 protein, vectors comprising an isolated nucleic acid molecule encoding a vhh-1 protein, mammalian cells comprising such vectors, antibodies directed to a vhh-1 protein, nucleic acid probes useful for detecting a nucleic acid molecule encoding a vhh-1 protein, pharmaceutical compositions related to the vhh-1 proteins, nonhuman transgenic animals which express a normal or a mutant vhh-1 protein. This invention further provides methods for inducing differentiation of floor plate cell, motor neuron, generating ventral neurons and treatments for alleviating abnormalities associated with the vhh-1 protein.
    Type: Application
    Filed: April 11, 2003
    Publication date: January 8, 2004
    Applicant: The Trustees of Columbia University
    Inventors: Thomas M. Jessell, Jane Dodd, Henk Roelink, Thomas Edlund
  • Publication number: 20030104374
    Abstract: This invention provides isolated nucleic acids encoding a motor neuron restricted MNR2 protein, and a homeobox HB9 protein. Also provided are purified MNR2 and HB9 proteins, antibodies recognizing these proteins, transgenic animals expressing these proteins, and functionally equivalent analogs of these proteins. Finally, methods are disclosed for inducing differentiation of somatic motor neurons, and for treating diseases related to the lack of normally functioning motor neurons, neurodegenerative diseases, acute nervous system injury, and neuromuscular disease.
    Type: Application
    Filed: March 29, 2001
    Publication date: June 5, 2003
    Inventors: Thomas M. Jessell, Yasuto Tanabe, Christopher William
  • Patent number: 6566092
    Abstract: This invention provides an isolated nucleic acid molecule encoding a vhh-1 protein, an isolated protein which is a vhh-1 protein, vectors comprising an isolated nucleic acid molecule encoding a vhh-1 protein, mamunalian cells comprising such vectors, antibodies directed to a vhh-1 protein, nucleic acid probes useful for detecting a nucleic acid molecule encoding a vhh-1 protein, pharmaceutical compositions related to the vhh-1 proteins, nonhuman transgenic animals which express a normal or a mutant vhh-1 protein. This invention further provides methods for inducing differentiation of floor plate cell, motor neuron, generating ventral neurons and treatments for alleviating abnormalities associated with the vhh-1 protein.
    Type: Grant
    Filed: February 27, 1997
    Date of Patent: May 20, 2003
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Thomas M. Jessell, Jane Dodd, Henk Roelink, Thomas Edlund
  • Publication number: 20020197678
    Abstract: This invention provides an isolated nucleic acid molecule encoding a motor neuron restricted pattern, MNR2, protein. This invention provides an isolated nucleic acid molecule of at least 15 contiguous nucleotides capable of specifically hybridizing with a unique sequence included within the sequence of the nucleic acid molecule encoding a MNR2 protein. This invention provides a purified MNR2 protein, a polyclonal and monoclonal antibody directed to an epitope of an MNR2 protein. This invention provides a method of inducing differentiation somatic motor neurons which comprises expressing MNR2 protein in any neural progenitor cells. This invention provides a transgenic animal which expresses an MNR2 protein. This invention provides a pharmaceutical composition comprising a MNR2 protein and pharmaceutically acceptable carrier.
    Type: Application
    Filed: March 11, 2002
    Publication date: December 26, 2002
    Applicant: The Trustees of Columbia University in the City of New York
    Inventors: Thomas M. Jessell, Yasuto Tanabe, Christopher William
  • Publication number: 20020132334
    Abstract: This invention provides an isolated vertebrate nucleic acid molecule which encodes dorsalin-1. This invention also provides a nucleic acid probe capable of specifically hybridizing with a sequence included within the sequence of a nucleic acid molecule encoding a dorsalin-1. The invention also provides a vector and host vector system for the production of a polypeptide having the biological activity of dorsalin-1 which comprises the above-described vector in a suitable host. This invention also provides a purified vertebrate dorsalin-1. This invention provides a method for stimulating neural crest cell differentiation, a method for regenerating nerve cells, a method for promoting bone growth, a method for promoting wound healing and a method for treating neural tumor using purified dorsalin-1. This invention further provides a pharmaceutical composition comprising purified dorsalin-1 and a pharmaceutically acceptable carrier. Finally, this invention provides an antibody capable of binding to dorsalin-1.
    Type: Application
    Filed: November 2, 2001
    Publication date: September 19, 2002
    Applicant: The Trustees of Columbia University in the City of New York
    Inventors: Thomas M. Jessell, Konrad Basler, Toshiya Yamada
  • Patent number: 6387656
    Abstract: This invention provides an isolated nucleic acid molecule encoding a motor neuron restricted pattern, MNR2, protein. This invention provides an isolated nucleic acid molecule of at least 15 contiguous nucleotides capable of specifically hybridizing with a unique sequence included within the sequence of the nucleic acid molecule encoding a MNR2 protein. This invention provides a purified MNR2 protein, a polyclonal and monoclonal antibody directed to an epitope of an MNR2 protein. This invention provides a method of inducing differentiation somatic motor neurons which comprises expressing MNR2 protein in any neural progenitor cells. This invention provides a transgenic animal which expresses an MNR2 protein. This invention provides a pharmaceutical composition comprising a MNR2 protein and pharmaceutically acceptable carrier.
    Type: Grant
    Filed: September 29, 1998
    Date of Patent: May 14, 2002
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Thomas M. Jessell, Yasuto Tanabe, Christopher William
  • Patent number: 6379961
    Abstract: This invention provides a composition comprising an amount of a purified protein selected from a group consisting of bone morphogenetic protein 4, bone morphogenetic protein, bone morphogenetic protein 7, dorsalin-1 and combinations thereof effective to stimulate neural crest cell differentiation and an acceptable carrier. This invention provides different uses of this composition.
    Type: Grant
    Filed: September 20, 1996
    Date of Patent: April 30, 2002
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Thomas M. Jessell, Karel F. Liem, Jr., Gabi Tremml
  • Patent number: 6333168
    Abstract: This invention provides an isolated vertebrate nucleic acid molecule which encodes dorsalin-1. This invention also provides a nucleic acid probe capable of specifically hybridizing with a sequence included within the sequence of a nucleic acid molecule encoding a dorsalin-1. The invention also provides a vector and host vector system for the production of a polypeptide having the biological activity of dorsalin-1 which comprises the above-described vector in a suitable host. This invention also provides a purified vertebrate dorsalin-1. This invention provides a method for stimulating neural crest cell differentiation, a method for regenerating nerve cells, a method for promoting bone growth, a method for promoting wound healing and a method for treating neural tumor using purified dorsalin-1. This invention further provides a pharmaceutical composition comprising purified dorsalin-1 and a pharmaceutically acceptable carrier. Finally, this invention provides an antibody capable of binding to dorsalin-1.
    Type: Grant
    Filed: May 20, 1993
    Date of Patent: December 25, 2001
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Thomas M. Jessell, Konrad Basler, Toshia Yamada